Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Impact of American Academy of Pediatrics Palivizumab Guidance for Children ≥29 and <35 Weeks of Gestational Age. J Pediatr 2019 06;209:125-129

Date

04/07/2019

Pubmed ID

30952507

DOI

10.1016/j.jpeds.2019.02.020

Scopus ID

2-s2.0-85063609964   8 Citations

Abstract

OBJECTIVES: To evaluate the impact of the American Academy of Pediatrics revised recommendations (2014) for palivizumab prophylaxis on respiratory syncytial virus (RSV) admissions and severity of illness among children ≥29 weeks and <35 weeks of gestational age.

STUDY DESIGN: We evaluated patients hospitalized with RSV infection from October 1, 2012, through April 30, 2017. RSV hospitalizations, community RSV activity, duration of hospitalization, disease severity, and mortality were reviewed. Data were compared before and after implementation of the guideline changes.

RESULTS: A total of 91 patients were born at ≥29 weeks and <35 weeks of gestational age and hospitalized within the first year of life during the evaluation period. Gestational age, birth weight, age at diagnosis, and sex remained constant over the seasons evaluated. RSV hospitalizations and activity in the community were unchanged over 5 years. Duration of hospitalization increased. There was no difference in need for intensive care, supplemental oxygen, or mechanical ventilation or mortality.

CONCLUSIONS: Implementation of the 2014 American Academy of Pediatrics guidelines regarding eligibility for palivizumab prophylaxis in older infants born preterm did not increase RSV hospitalizations or disease severity among children hospitalized for RSV at our hospital. Our data support continued adherence to the guidelines.

Author List

Zembles TN, Bushee GM, Willoughby RE

Author

Rodney E. Willoughby MD Professor in the Pediatrics department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Academies and Institutes
Antiviral Agents
Female
Gestational Age
Humans
Infant
Infant, Newborn
Male
Palivizumab
Patient Admission
Pediatrics
Practice Guidelines as Topic
Respiratory Syncytial Virus Infections
Retrospective Studies
Severity of Illness Index